CV Lattes
ORCID
Abstract
Chemotherapy-induced neuropathic pain (CINP) has a very high prevalence (between 50% and 80% of cases), negatively impacting patients' quality of life and potentially leading to treatment discontinuation. Preventive or symptomatic treatments for CINP are generally ineffective, making it necessary to investigate new therapeutic approaches that can prevent or improve these symptoms. In this…